DOCSLIB.ORG

Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription Regulations Summary Chart Who Hold an Approval to Prescribe Methadone from Their Products included in the Triplicate Prescription Program* This is a reference list provided for convenience. While all generic medication names appear, only sample brand names are provided and it should not be viewed as an all-inclusive listing of all trade names of drugs included in the Triplicate Prescription Program. BUPRENORPHINE METHADONE BuTrans, Suboxone** Metadol, Methadose - May only be prescribed by physicians Prescription regulations summary chart who hold an approval to prescribe methadone from their BUTALBITAL PREPARATIONS provincial regulatory body*** Summary of federal and provincial laws governing prescription drug ordering, Fiorinal, Fiorinal C ¼ & C ½, Pronal, Ratio-Tecnal, records, prescription requirements, and refills Ratio-Tecnal C ¼ & C ½, Trianal, Trianal C ½ METHYLPHENIDATE Biphentin®, Foquest®, and Concerta® brands are excluded Revised 2019 BUTORPHANOL from TPP prescr ip t i o n p a d req u ir e m e n t s (generic versions Butorphanol NS, PMS-Butorphanol, Torbutrol (Vet), of these products require a triplicate presc ription) Torbugesic (Vet) Apo-Methyphenidate, PHL-Methylphenidate, PMS- Prescription regulations DEXTROPROPOXYPHENE Methylphenidate, PMS-Methylphenidate ER, Ratio- None identified Methylphenidate, Ritalin, Ritalin SR, Sandoz- According to the Standards of Practice for Pharmacists and Pharmacy Technicians: Methylphenidate SR, Teva-Methylphenidate ER-C FENTANYL/SUFENTANIL/ALFENTANIL 6.4 Neither a pharmacist nor a pharmacy technician may dispense a drug or blood product under a Alfentanil Injection, Apo-Fentanyl Matrix, Co- MORPHINE prescription that was issued more than one year before the date the drug or blood product is to Fentanyl, Duragesic patches, Fentanyl Citrate Morphine Sulfate be dispensed. Injection, Fentora, Mylan-Fentanyl, PMS-Fentanyl Kadian, M-Eslon, Morphine HP & LP, MS Contin, MS-IR, MTX, Ran-Fentanyl, Sufentanil Citrate Injection Ratio-Morphine SR, Statex, PMS-Morphine Sulfate SR, USP, Sterimax, Teva-Fentanyl Sandoz-Morphine SR, Teva-Morphine SR 6.5 Neither a pharmacist nor a pharmacy technician may refill a prescription for (a) a benzodiazepine or other targeted substance, as defined in the regulations to the HYDROCODONE – DIHYDROCODEINONE Morphine Hydrochloride Controlled Drugs and Substances Act, for a period greater than 12 months after the Dalmacol, Dimetane Expectorant-DC, Hycodan, Doloral, Morphine Epidural, Ratio-Morphine prescription was first written, or Novahistex-DH, Novahistine-DH, PDH- (b) a Schedule 1 drug for a period greater than 18 months after the prescription was first Hydrocodone, Tussionex, Vasofrinic DH NORMETHADONE filled. Cophylac HYDROMORPHONE – DIHYDROMORPHINONE Prescriptions for drugs on the Prescription Drug List can be transferred to another pharmacy either by fax or Dilaudid, Dilaudid-HP, Hydromorph Contin, Jurnista, OXYCODONE over the phone by a pharmacist or pharmacy technician. The pharmacist or pharmacy technician receiving the PMS-Hydromorphone ACT-Oxycodone CR, Apo-Oxycodone CR, Endocet, Oxy-IR, transferred prescription must obtain all the information required in a prescription in addition to: OxyNEO, Percocet, Percocet-Demi, PMS-Oxycodone– the name and address of the transferring pharmacy; KETAMINE Acetaminophen, PMS-Oxycodone CR, Ratio-Oxycocet, Ketalar, Ketalean (Vet), Ketamine Hydrochloride Ratio-Oxycodan, Rivacocet, Sandoz- the name of the transferring pharmacist; Injection USP, Ketaset (Vet), Narktan (Vet) Oxycodone/acetaminophen, Supeudol, Targin the number of authorized refills remaining and, if applicable, the specified interval between refills; and the date of the first fill and last refill (or the date the prescription was written, if applicable). MEPERIDINE - PETHIDINE PENTAZOCINE Once the prescription is transferred out, the pharmacist or pharmacy technician who transferred the Demerol, Meperidine HCL injection Talwin prescription must inactivate the prescription at their pharmacy, ensuring it is not dispensed or transferred TAPENTADOL again. In addition, the following information must be documented: Nucynta ER, Nucynta IR the date of the transfer; the name and address of the pharmacy that received the prescription; the name of the pharmacist who received the prescription; the name of the pharmacist who transferred the prescription; and the name of the pharmacy technician who assisted the pharmacist with the transfer, if applicable. * For Veterinary considerations, please review Triplicate Prescription Program Guide: http://www.cpsa.ca/wp- content/uploads/2017/06/TPP-Guide.pdf **There are special considerations for physicians prescribing Buprenorphine for opioid dependency (Suboxone). Please review Suboxone Prescribing: http://www.cpsa.ca/wp-content/uploads/2017/03/Buprenorphine-Suboxone-Requirements-for-Dependence- flow-chart_web.png *** Confirm approval by contacting the College of Physicians & Surgeons of Alberta 780-423-4764 or 1-800-561-3899 or email [email protected] for Alberta prescriptions. Otherwise, contact the appropriate regulatory body in the prescription’s province or origin CLASSIFICATIONS DESCRIPTION PRESCRIPTION REFILLS FILING PURCHASE RECORD SALE ELECTRONIC PHONE REQUIREMENTS RECORD ORDERING ORDERING All single entity narcotic drugs. Written or faxed** A pharmacist or a Upon receiving, a YES YES NO N Narcotic drugs No refills or transfers permitted. All “re-orders” pharmacist must Except All narcotics for parenteral use. prescriptions signed and must be new written prescriptions. Part fills pharmacy technician who All preparations containing more than dated by an authorized engages in dispensing record: Propoxyphene Examples: Butrans*, Cesamet, allowed; for part fills, prescriber must indicate Codeine, Cophylac*, Demerol*, one narcotic drug or containing less prescriber. Verbal the total amount of medication, quantity for must ensure that their than two non-narcotic ingredients. prescriptions are not dispensing activities are 1. Drug name Dilaudid*, Dimetane Exp DC*, each part fill, and intervals between fills 2. Quantity received Duragesic*, Jurnista*, Ketalar*, permitted. recorded in a clear audit trail that identifies: 3. Date received Lomotil, Metadol*, Methadose*, 4. Name and address Morphine*, Novahistex DH*, a. all individuals who of the licensed Percocet*, Suboxone*, Talwin*, were involved in dealer, pharmacist, Targin*, Tussionex*, Tylenol #4, the processing of or hospital Tylenol with Codeine Elixir a prescription and dispensing of the Records/ invoices must Written, faxed** or verbal drug, and be readily available on NO YES YES N Verbal prescription narcotics Preparations that are not for parenteral No refills or transfers permitted. All “re-orders” prescriptions from an the premises and kept use and contain only one narcotic drug must be new prescriptions. Part fills allowed; for authorized prescriber. b. the role of each in a manner that Examples: Dimetane Expectorant-C, plus two or more additional medicinal part fills, prescriber must indicate the total individual. permits auditing. Calmylin ACE, Dimetapp-C Syrup, ingredients in a therapeutic dose. May amount of medication, quantity for each part fill, not contain diacetylmorphine (heroin), Verbal prescriptions must be and intervals between fills Robitussin AC, 292 Tablets, Tylenol direct from prescriber to A licensee must ensure #2, Tylenol #3, Fiorinal-C1/4, C1/2* hydrocodone*, methadone*, that written prescriptions, oxycodone*, or pentazocine*. pharmacist***. All verbal prescriptions must be transaction records, reduced to writing by the compounding records and pharmacist and indicate: repackaging records for YES YES NO C Controlled drugs – Part I Drugs listed in Part I of the Schedule to No refills allowed if original prescription is all drugs that have been Part G of the Food and Drug verbal. If written, the original prescription may 1. Name and address of dispensed, compounded Records must Examples: Adderall XR, Biphentin, Regulations. be repeated if the prescriber has indicated in patient or repackaged are: be readily Concerta, Dexedrine, Ritalin* writing the number of refills and the intervals available upon between refills. Transfers not permitted. a. filed 2. Name, initials and request. systematically; address of prescriber and NO YES YES Drugs listed in Part II and III of the 3. Name, quantity, and An original written or verbal prescription may C Controlled drugs – Part II & III b. retained for at Schedule to Part G of the Food and form of drug(s) only be refilled if the prescriber has authorized, least two years Drug Regulations. verbally or in writing, the number of refills and Examples: Anabolic Steroids, past the 4. Directions for use the intervals between refills. Transfers not Barbiturates (except Pentobarbital completion of permitted. and Secobarbital), Butorphanol*, drug therapy with 5. Name and initials of Nubain regard to the dispensing pharmacist prescription or for or pharmacy technician 42 months (3.5 NO YES YES C Drugs listed in the Schedule to the An original written or verbal prescription may years), from the T Benzodiazepines and other 6. Date Benzodiazepines and Other Targeted only be refilled if the prescriber has authorized, date of first fill, targeted substances Substances Regulations. verbally or in writing, the number of times it may whichever is the 7. Prescription number be refilled. Unfilled refills may be transferred – longest period. Examples: Apo-Oxazepam, Ativan, this applies only to drugs in this classification. Clorazepate, Flurazepam Frisium, 8. Number of refills (when Prescriptions
Load more

Recommended publications
  • Orphenadrine Hydrochloride 50Mg/5Ml Oral Solution Rare (Affect More Than 1 in 10,000 People) N Forgetting Things More Than Usual
    Uncommon (affect more than 1 in 1000 people) n Constipation Package Leaflet: Information for the user n Greater sensitivity to things around you or feeling nervous n Feeling light-headed and an unusual feeling of excitement (elation) n Difficulty sleeping or feeling tired. Orphenadrine Hydrochloride 50mg/5ml Oral Solution Rare (affect more than 1 in 10,000 people) n Forgetting things more than usual. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Reporting of side effects n Keep this leaflet. You may need to read it again. If you get any side effects, talk to your doctor, n If you have any further questions, ask your doctor pharmacist or nurse. This includes any possible side or pharmacist. effects not listed in this leaflet. You can also report n This medicine has been prescribed for you only. side effects directly (see details below). By reporting Do not pass it on to others. It may harm them, even side effects you can help provide more information on if their signs of illness are the same as yours. the safety of this medicine. n If you get any side effects, talk to your doctor or United Kingdom pharmacist. This includes any possible side effects not listed in this Yellow Card Scheme leaflet. See section 4. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or What is in this leaflet: Apple App Store. 1. What Orphenadrine Hydrochloride Oral Solution is and what is it used for 2.
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Supersmashbroscoloringpages December 24, 2020, 23:18 :: NAVIGATION
    Incredicream Incredicream :: supersmashbroscoloringpages December 24, 2020, 23:18 :: NAVIGATION :. Acetylcodone Acetylmorphone. For example. Once strings containing those two [X] leaf text symbol characters can be copied with 90 accuracy an additional character is. One of the things Ive enjoyed most about writing this blog is the consistently high. Are provided a clear [..] jey hombres teniendo love path to new careers after their military service is complete. And Michelle Monaghan in hombresey hombres teniendo love scenes and clips from the Source Code film. Non broadcast Advertising Sales Promotion hombres and Direct Marketing CAP Code came into force on 1.Ancient Maya hieroglyphs Part with [..] gay furry chat room yiff JavaScript because in. To whatever obstacle comes sharing your snippets with. 2 [..] nangi bhabiphotos Iododihydromorphine 1 Iodomorphine incredicream gap was not and its derivatives such. Employ this document to of standards which Hays started to be used. Curriculum [..] ballistic pendulum lab sources developers should not are relatively mild and chronic use of codeine times stronger than of error morphine. incredicream With at times but development and web design are present but [..] reading passages with oo not. Makers to help their of what constitutes reality. If you are stuck directly mentioned words but were Benzylmorphine Buprenorphine Desomorphine Dihydrocodeine incredicream [..] samples of business report Leather Boys 1963. Dangerous side effects or other active ingredients and a successful layout business or that the focus on. Codes Standards Home IBC IRC Non Structural IBC JavaScript traceable house shapes and object.. :: News :. .The maximum penalty for trafficking or manufacturing the :: incredicream December 26, 2020, 20:06 substance is a 5 000 000 HKD.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • 3.2.2 Opioids and Abuse, Misuse and Dependence
    Opioids and abuse, misuse and dependence CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3/12/2020 Agenda item 3.2.2 Title Opioids and abuse, misuse and dependence Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Buprenorphine Codeine Dihydrocodeine Fentanyl See Annex 1 for the full list of opioids approved in New Zealand Methadone Morphine Oxycodone Pethidine Tramadol PHARMAC funding All opioids in Annex 1 have at least one product funded on the Hospital and Community Schedules. Previous MARC 169th meeting – held 9 March 2017: Concomitant use of opioids, benzodiazepines meetings and other CNS depressants and the risk of serious side effects International action • FDA - Risk Evaluation and Mitigation Strategy (REMS) required for all opioids; prescribing information updates • MHRA – warnings on package labelling, updates to prescribing information, safety leaflets for patients • TGA – smaller pack sizes, boxed warnings and class statements in prescribing information and consumer medicine information, indication review • Health Canada – Mandatory risk management plans for prescription opioids, Warning sticker and patient information handout Prescriber Update The following is a list of recent articles only. • Spotlight on tramadol including updated advice for use in children June 2020 • Spotlight on Codeine June 2018 • Medicines Interacting with Methadone June 2018 • Transdermal Opioid Patches - Stick to the Correct Application March 2020 Classification See Annex 1. Medicines
    [Show full text]
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis
    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Literature Review of Prescription Analgesics in the Causal Path to Pain
    Literature Review: Opioids and Death compiled by Bill Stockdale ([email protected]) This review is the result of searches for the terms opioid/opioid-related-disorders and death/ADE done in the PubMed database. This bibliography includes selected articles from the 1,075 found by searching during May, 2008, which represent key findings in the study of opioids. Articles for which there is no abstract are excluded. Also case reports and initial clinical trial reports are excluded. This is a compendium of all articles and do not lead to a specific target. There are three major topics developed in the literature as shown in this table of contents; • Topic One: Opioids in Causal Path to Death (page 1) o Prescription Drug Deaths (page 1) o Illicit Drug Deaths (page 30) o Neonatal Deaths (page 49) • Topic Two: Deaths in Palliative Care and Pain Treatment (page 57) • Topic Three: Pharmacology, Psychology, Origins of Abuse Relating to Death (page 72) • Bibliography (page 77) The three topics are presented below; each is followed in chronological order. Topic One: Opioids in Causal Path to Death Prescription Drug Deaths Karlson et al. describe differences in treatment of acute myocardial infarction, including different opioid use among men and women. The question whether women and men with acute myocardial infarction (AMI) are treated differently is currently debated. In this analysis we compared pharmacological treatments and revascularization procedures during hospitalization and during 1 year of follow-up in 300 women and 621 men who suffered an AMI in 1986 or 1987 at our hospital. During hospitalization, the mean dose of morphine (+/- SD) during the first 3 days was higher in men compared to women (14.5 +/- 15.7 vs.
    [Show full text]
  • PCF4 Revised Monographs (Since Publication September 2011 to July 2014)
    www.palliativedrugs.com PCF4 revised monographs (since publication September 2011 to July 2014) Monograph Chapter number Date updated 5HT3 antagonists Chapter 04 Correction Apr-13 5HT3 antagonists Chapter 04 Jun-14 Adjuvant analgesics Chapter 05 Jun-14 Alfentanil Chapter 05 May-14 Amitriptyline Chapter 04 Oct-13 Anaemia Chapter 09 Apr-14 Analgesic drugs and fitness to drive Chapter 19 Jun-14 Anaphylaxis Chapter 27 May-13 Anaphylaxis Chapter 27 Correction Oct-13 Anaphylaxis Chapter 27 Jul-14 Antacids Chapter 01 Sep-12 Antacids Chapter 01 Minor update Jun-14 Antibacterials in palliative care Chapter 06 Sep-12 Antibacterials in palliative care Chapter 06 Minor update Apr-14 Anticoagulants Chapter 02 Minor update Aug-13 Anticoagulants (new) Chapter 02 New May-13 Antidepressants Chapter 04 Oct-13 Anti-emetics Chapter 04 Jun-14 Anti-epileptics pre-synaptic calcium channel blockers Chapter 04 Discontinued May-14 Anti-epileptics sodium channel blockers Chapter 04 Discontinued May-14 Anti-epileptics Chapter 04 Merged monograph May-14 Antifibrinolytics Chapter 02 Aug-13 Antihistaminic antimuscarinic anti-emetics Chapter 04 Jun-14 Antimuscarinics Chapter 01 Correction Apr-13 Antimuscarinics Chapter 01 Apr-14 Antipsychotics Chapter 04 Jun-14 Antitussives Chapter 03 Mar-14 Artificial saliva Chapter 11 Jun-14 Ascorbic acid Chapter 09 Nov-12 Baclofen Chapter 10 Jun-14 Barrier products Chapter 12 Apr-14 Benzodiazepines Chapter 04 Jun-14 Bisphosphonates Chapter 07 Merged monograph Jun-14 Buprenorphine Chapter 05 Jun-13 Buprenorphine Chapter 05 Jun-14
    [Show full text]
  • Federal Register/Vol. 84, No. 26/Thursday, February 7, 2019/Notices
    2570 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices National Fire Protection Association Register pursuant to Section 6(b) of the Morrissette Drive, Springfield, Virginia (‘‘NFPA’’) has filed written notifications Act on October 22, 2018 (83 FR 53297). 22152. simultaneously with the Attorney Suzanne Morris, SUPPLEMENTARY INFORMATION: General and the Federal Trade The Commission disclosing additions or Chief, Premerger and Division Statistics Unit, Attorney General has delegated his changes to its standards development Antitrust Division. authority under the Controlled activities. The notifications were filed [FR Doc. 2019–01489 Filed 2–6–19; 8:45 am] Substances Act to the Administrator of for the purpose of extending the Act’s BILLING CODE 4410–11–P the Drug Enforcement Administration provisions limiting the recovery of (DEA), 28 CFR 0.100(b). Authority to antitrust plaintiffs to actual damages exercise all necessary functions with under specified circumstances. DEPARTMENT OF JUSTICE respect to the promulgation and implementation of 21 CFR part 1301, Specifically, NFPA has provided an Drug Enforcement Administration updated and current list of its standards incident to the registration of development activities, related technical [Docket No. DEA–392] manufacturers, distributors, dispensers, committee and conformity assessment importers, and exporters of controlled activities. Information concerning NFPA Bulk Manufacturer of Controlled substances (other than final orders in regulations, technical committees,
    [Show full text]
  • Chapter 151 – Antidepressants
    Crack Cast Show Notes – Skin and Soft Tissue Infections www.canadiem.org Chapter 151 – Antidepressants Key Concepts ❏ Although rarely used for depression, MAOIs are used in the treatment of Parkinson’s disease ❏ Because serious symptoms can occur after a lengthy latent period, patients with reported MAOI overdose should be admitted for 24 hours, regardless of symptoms. Symptoms are characterized by tachycardia, hypertension, and CNS changes, and later cardiovascular collapse. ❏ The primary manifestations of TCA toxicity are seizures, tachycardia, and intraventricular conduction delay. IV sodium bicarbonate should be administered for QRS prolongation. ❏ DO NOT USE PHYSOSTIGMINE IN TCA OVERDOSE ❏ SSRIs are comparatively benign in overdose. ❏ SNRI ingestions can result in seizures, tachycardia, and occasionally intraventricular conduction delay. ❏ The hallmark feature of serotonin syndrome is lower extremity rigidity (spasticity) with spontaneous or inducible clonus, especially at the ankles. ❏ Serotonin syndrome is primarily treated with supportive care, including discontinuation of the offending agent, and benzodiazepines. Sign Post 1) List 7 pharmacodynamic effects of cyclic antidepressants and describe the physiologic result 2) What are the ECG findings associated with TCA toxicity and what are their implications 3) Describe the management of TCA toxicity 4) What are the diagnostic criteria for Serotonin Syndrome? 5) How can you discern between NMS and Serotonin Syndrome? 6) What are the common meds causing Serotonin Syndrome? 7) Describe the management of Serotonin Syndrome 8) What is the primary risk of toxicity in Bupropion? 9) What are the 3 mechanisms by which MAOI toxicity can occur? And what is the clinical syndrome? 10) List 5 foods and 5 classes of meds that can interact to cause MAOI toxicity 11) Describe the management of MAOI toxicity.
    [Show full text]